The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
Open accessAbstract
There is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. Accumulating preclinical evidence emphasizes the role of the glutamate system in the acute action of the drug on brain and behavior; however this has never been tested in humans. Following a double-blind, placebo-controlled, parallel group design, we utilized an ultra-high field multimodal brain imaging approach and demonstrated that psilocybin (0.17 mg/kg) induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution). Whereas higher levels of medial prefrontal cortical glutamate were associated with negatively experienced ego dissolution, lower levels in hippocampal glutamate were associated with positively experienced ego dissolution. Such findings provide further insights into the underlying neurobiological mechanisms of the psychedelic, as well as the baseline, state. Importantly, they may also provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Raincloud plots displaying metabolite concentrations in the mPFC and the hippocampus, which demonstrated significant differences between treatment groups. a glutamate in the mPFC, b NAA in the mPFC, c glutamate in the hippocampus, d GABA in the mPFC. The plot consists of a probability density plot, a boxplot, and raw data points. In the boxplot, the line dividing the box represents the median of the data, the ends represent the upper/lower quartiles, and the extreme lines represent the highest and lowest values excluding outliers. The code for raincloud plot visualization has been adapted from Allen et al. [99].](/paper-figures/c830fa3cb891411e99e26af3030e1d35/me-myself-bye-regional-alterations-in-glutamate-and-the-experience-of-ego-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The potential of classic psychedelics to alter glutamate in the human cortex, albeit in a region-dependent manner, has been demonstrated (92).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190
Correspondence of the brain's functional architecture during activation and rest
Smith, S. M., Fox, P. T., Miller, K. L., Glahn, D. C., Fox, P. M., Mackay, C. E., Filippini, N., Watkins, K. E., Toro, R., Laird, A. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905267106 · Cited by 5,150
Conn : A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks
Whitfield-Gabrieli, S., & Nieto-Castanon, A. (2012) · Brain Connectivity · doi:10.1089/brain.2012.0073 · Cited by 4,885
A method for making group inferences from functional MRI data using independent component analysis
Calhoun, V. D., Adali, T., Pearlson, G. D., & Pekar, J. J. (2001) · Human Brain Mapping · doi:10.1002/hbm.1048 · Cited by 2,994
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“A paradoxical effect of serotonergic psychedelics is that acutely they have been found to increase feelings of anxiety [6, 78], whereas clinical trials with psychedelic drugs suggest long-term anxiety relief in patients [11, 12, 14].”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationBunney, W. E., Hippius, H., Laakmann, G., & Schmauß, M. (1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
A Baseline for the Multivariate Comparison of Resting-State Networks
Allen, E. A., Erhardt, E. B., Damaraju, E., Gruner, W. E., Segall, J. M., Silva, R. F., Havlíček, M., Rachakonda, S., Fries, J. F., Kalyanam, R., et al. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00002 · Cited by 1,329
Cited by
Sorted by citations
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 308
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Self-citationDefault Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2021) · Brain · doi:10.1093/brain/awab406 · Cited by 217
Timmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150
Madsen, M. K., Stenbæk, D. S., Arvidsson, A., Armand, S., Marstrand-Joergensen, M. R., Johansen, S. S., Línnet, K., Ozenne, B., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.001 · Cited by 155
Spontaneous and deliberate creative cognition during and after psilocybin exposure
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T., Müller, F., Tse, D. H. Y., Rios, B. D., Toennes, S. W., Stiers, P. L. J., Feilding, A., & Ramaekers, J. G. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01335-5 · Cited by 144
Self-citationMolecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 126
Self-citationClassic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 119
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 110
Self-citationWojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Szych, Z., Majcher‐Maślanka, I., Herian, M., Maćkowiak, M., & Gołembiowska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126713 · Cited by 114
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Canalization and plasticity in psychopathology
Carhart-Harris, R. L., Chandaria, S., Erritzøe, D., Gazzaley, A. H., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D. J., Rosas, F. E., Roseman, L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109398 · Cited by 107
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 119
Psychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 94
Self-citationPsychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“Inaddition to peripheral measurement of BDNF, another read-out of the effect of psychedelic compound binding of the 5-HT 2A R in human brain, is glutamate release, which unlike BDNF measurements, can be readily quantified in human brain (Dos Santos and Hallak, 2020; Mason et al., 2020).”
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 96
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83
Garland, E. L. (2021) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2021.03.019 · Cited by 85
A complex systems perspective on psychedelic brain action
Girn, M., Rosas, F. E., Daws, R. E., Gallen, C. L., Gazzaley, A. H., & Carhart-Harris, R. L. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2023.01.003 · Cited by 79
van Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74
Self-citationAn Integrated theory of false insights and beliefs under psychedelics
McGovern, H. T., Grimmer, H. J., Doss, M. K., Hutchinson, B. T., Timmermann, C., Lyon, A., Corlett, P. R., & Laukkonen, R. (2024) · Communications Psychology · doi:10.1038/s44271-024-00120-6 · Cited by 79
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences
Ballentine, G., Friedman, S. F., & Bzdok, D. (2022) · Science Advances · doi:10.1126/sciadv.abl6989 · Cited by 62
Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities
Yaden, D. B., Johnson, M. W., Griffiths, R. R., Doss, M. K., Garcia‐Romeu, A., Nayak, S. M., Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab026 · Cited by 69
Smausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 65
Sustained effects of single doses of classical psychedelics in humans
Knudsen, G. M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01361-x · Cited by 67
Cardiovascular safety of psychedelic medicine: current status and future directions
Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 71
Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 63
Burt, J. B., Preller, K. H., Demirtaş, M., Ji, J. L., Krystal, J. H., Vollenweider, F. X., Anticevic, A., & Murray, J. D. (2021) · eLife · doi:10.7554/elife.69320 · Cited by 48
Doss, M. K., May, D. G., Johnson, M. W., Clifton, J. M., Hedrick, S. L., Prisinzano, T. E., Griffiths, R. R., & Barrett, F. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-73216-8 · Cited by 50
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
Glowacki, D. R., Williams, R. R., Wonnacott, M., Maynard, O., Freire, R., Pike, J. E., & Chatziapostolou, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-12637-z · Cited by 64
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 60
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 52
Hudak, J., Hanley, A. W., Marchand, W. R., Nakamura, Y., Yabko, B. A., & Garland, E. L. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00831-4 · Cited by 49
Prefrontal contributions to the stability and variability of thought and conscious experience
Zamani, A., Carhart-Harris, R. L., & Kalina Christoff, A. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01147-7 · Cited by 49
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decen-tration, potentially leading to therapeutic outcomes [42, 43].”
BackgroundOnofrj, M., Russo, M., Delli Pizzi, S., De Gregorio, D., Inserra, A., Gobbi, G., & Sensi, S. L. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02691-0 · Cited by 43
Passie, T., Adams, H.-A., Logemann, F., Brandt, S. D., Wiese, B., & Karst, M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.005 · Cited by 47
Olsen, A. S., Lykkebo-Valløe, A., Ozenne, B., Madsen, M. K., Stenbæk, D. S., Armand, S., Mørup, M., Ganz, M., Knudsen, G. M., & Fisher, P. M. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119716 · Cited by 40
Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 38
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
Bedford, P., Hauke, D. J., Wang, Z., Röth, V., Nagy-Huber, M., Holze, F., Ley, L., Vizeli, P., Liechti, M. E., Borgwardt, S., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01574-8 · Cited by 42
Self-citationPsilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 49
IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy
Mash, D. C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106620 · Cited by 42
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 40
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 42
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G. K., Ching, T. H. W., Belser, A., & Pittenger, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12135 · Cited by 44
Psilocybin-Assisted Compassion Focused Therapy for Depression
Pots, W. T. M., & Chakhssi, F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.812930 · Cited by 35
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 41
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 33
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 35
Doss, M. K., Samaha, J., Barrett, F. S., Griffiths, R. R., de Wit, H., Gallo, D. A., & Koen, J. D. (2023) · Psychological Review · doi:10.1037/rev0000455 · Cited by 33
Beating pain with psychedelics: Matter over mind?
Elman, I., Pustilnik, A. C., & Borsook, D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.005 · Cited by 30
Roscoe, J., & Lozy, O. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221085222 · Cited by 33
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 33
Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 33
Buchborn, T., Kettner, H., Kärtner, L., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1232459 · Cited by 30
Rapid-acting antidepressant drugs modulate affective bias in rats
Hinchcliffe, J. K., Stuart, S. A., Wood, C. M., Bartlett, J. M., Kamenish, K., Arban, R., Thomas, C. W., Selimbeyoglu, A., Hurley, S., Hengerer, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2403 · Cited by 29
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Ponomarenko, P., Seragnoli, F., Calder, A. E., Oehen, P., & Hasler, G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231155117 · Cited by 31
Mortaheb, S., Fort, L. D., Mason, N. L., Mallaroni, P., Ramaekers, J. G., & Athena Demertzi, A. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.04.001 · Cited by 31
Self-citationSzpręgiel, I., & Bysiek, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00660-y · Cited by 28
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 29
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24
Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2023) · Network Neuroscience · doi:10.1162/netn_a_00349 · Cited by 21
Self-citationAn international mega-analysis of psychedelic drug effects on brain circuit function
Girn, M., Doss, M. K., Roseman, L., Preller, K. H., Palhano-Fontes, F., Pasquini, L., Barrett, F. S., Mallaroni, P., Mason, N. L., Timmermann, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04287-9 · Cited by 29
Self-citationDworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22
The use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 25
Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power
Meikle, S. E., Carter, O. L., & Bedi, G. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231200164 · Cited by 25
Inter-individual variability in neural response to low doses of LSD
Hutten, N. R. P. W., Quaedflieg, C. W. E. M., Mason, N. L., Theunissen, E. L., Liechti, M. E., Duthaler, U., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03013-8 · Cited by 22
Self-citationOtto, M. E., van der Heijden, K. V., Schoones, J. W., van Esdonk, M. J., Borghans, L. G. J. M., Jacobs, G. E., & van Hasselt, J. G. C. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01454-4 · Cited by 24
Brito, M. A., Li, D., Fields, C. W., Rybicki-Kler, C., Dean, J. G., Liu, T., Mashour, G. A., & Pal, D. (2021) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005835 · Cited by 20
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21
The Health and Clinical Benefits of Medicinal Fungi
Hobbs, C. (2023) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2023_230 · Cited by 24
Singh, N., Hazari, P. P., Mittal, P., Yadav, S. K., Kumar, N., Mishra, G., Dahiya, S., & Mishra, A. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177737 · Cited by 24
A novel ego dissolution scale: A construct validation study
Sleight, F. G., Lynn, S. J., Mattson, R. E., & McDonald, C. W. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103474 · Cited by 22
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 22
Psilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Lee, H. J., Tsang, V. W. L., Chai, B. S., Lin, M. C., Howard, A. K., Uy, C. E., & Elefante, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2223195 · Cited by 21
Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation
Moujaes, F., Rieser, N. M., Phillips, C. L. M., de Matos, N. M. P., Brügger, M., Duerler, P., Smigielski, L., Stämpfli, P., Seifritz, E., Vollenweider, F. X., et al. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.07.003 · Cited by 25
Psychedelics action and schizophrenia
Maćkowiak, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00546-5 · Cited by 22
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 24
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 25
Basedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 19
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20
“Many consider it to be a typical effect of both LSD and psilocybin (Mason et al., 2020; Tagliazucchi et al., 2016), particularly at higher doses (Holze et al., 2021).”
BackgroundBarrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 20
Wang, S., Kim, S., Choi, W.-S., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1134 · Cited by 19
Computational models of the “active self” and its disturbances in schizophrenia
Möller, T. J., Georgie, Y. K., Schillaci, G., Voss, M., Hafner, V. V., & Kaltwasser, L. (2021) · Consciousness and Cognition · doi:10.1016/j.concog.2021.103155 · Cited by 19
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 18
Armstrong, M., Castellanos, J. P., & Christie, D. (2024) · Frontiers in Pain Research · doi:10.3389/fpain.2024.1346053 · Cited by 19
Mallaroni, P., Mason, N. L., Vinckenbosch, F. R. J., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06142-4 · Cited by 16
Self-citationVeeraiah, P., & Jansen, J. F. A. (2023) · Metabolites · doi:10.3390/metabo13040577 · Cited by 16
Self-citation
Metadata
- Authors
- Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., & Ramaekers, J. G.
- Affiliations
- Maastricht University (NL)
- University of Basel (CH)
- Goethe University Frankfurt (DE)
- Maastricht University Medical Centre (NL)
- Beckley Foundation (GB)
- Corresponding author
- Mason, N. L.
- Ramaekers, J. G.
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2020-05-23
- Volume
- 45
- Issue
- 12
- Pages
- 2003-2011
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC7547711
- OpenAlex
- W3027590463
- Cited by
- 258
- References
- 102
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 40 · 2023: 62 · 2022: 42 · 2021: 32 · 2020: 5
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- Beckley Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psilocybin, glutamate, ego dissolution, self-experience, medial prefrontal cortex, hippocampus, subjective experience, psychedelics, depression, ultra-high field MRI
- MeSH terms
- Ego, Hallucinogens, Humans, Psilocybin, Solubility, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review